Filing identity and reporting period
The supplied filing is Theravance, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed February 27, 2012. It is not identified as an Innoviva filing; confirm the issuer and period before relying on this summary. Annual financial statements are audited; quarterly figures are unaudited.
Business context
Theravance was a research-stage biopharmaceutical company developing small-molecule medicines, with programs in respiratory disease, bacterial infections and CNS/pain. Its principal partnered programs—RELOVAIR, LAMA/LABA and MABA—were with GlaxoSmithKline (GSK). VIBATIV (telavancin) was its only approved product, while its other candidates remained in development.
Financial performance and position
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $24.5 million | $24.2 million |
| Research and development expense | $103.6 million | $75.1 million |
| General and administrative expense | $30.7 million | $27.5 million |
| Operating loss | $109.7 million | $78.3 million |
| Net loss | $115.3 million | $83.9 million |
| Basic and diluted loss per share | $1.41 | $1.16 |
| Operating cash used | $88.3 million | $75.1 million |
Revenue was largely collaboration-related, including deferred-fee amortization and VIBATIV royalties; it was not indicative of a profitable commercial business. The filing does not provide a meaningful positive profit margin. R&D rose 38%, primarily due to external program costs, clinical work in PμMA and MARIN, laboratory supplies and employee costs. Cash, cash equivalents and marketable securities were $240.9 million at year-end, down $68.7 million from 2010; working capital was $199.3 million. Current assets were $244.8 million against current liabilities of $45.5 million.
At December 31, 2011, convertible subordinated notes had $172.5 million principal outstanding, bore 3% interest and matured January 15, 2015. Total stockholders’ net capital deficiency was $87.1 million, and accumulated deficit was $1.316 billion. The company reported no dividends and no off-balance-sheet financial arrangements.
Fourth-quarter figures
For Q4 2011, revenue was $5.4 million, operating expenses $40.9 million, operating loss $35.6 million and net loss $37.0 million, or $0.45 per share. In Q4 2010, revenue was $6.9 million and net loss $19.3 million. The 2011 quarter included a $0.5 million charge for VIBATIV inventory deemed unrecoverable. Quarterly cash-flow figures are not provided in the supplied filing text.
Material changes and developments
- Annual net loss widened by $31.5 million from 2010, driven principally by higher R&D spending; operating cash use also increased by $13.2 million.
- In October 2011, Theravance expanded its GSK MABA collaboration to include six preclinical compounds, receiving a $1.0 million upfront payment and retaining potential milestone and royalty rights. GSK relinquished option rights over MARIN and ARNI.
- GSK’s 2011 equity purchases provided $13.6 million. Cash-flow financing proceeds were substantially below 2010, when the company completed a public offering and a GSK private placement.
- After year-end, Astellas terminated its VIBATIV collaboration on January 6, 2012. Theravance regained global rights; Astellas retained a 2% royalty on future net sales for ten years. The company expected to recognize about $125 million of remaining deferred fees and milestones as revenue in Q1 2012, net of estimated termination obligations; this was a noncash subsequent-event item, not 2011 revenue.
Outlook, risks and unusual items
Management said year-end cash and investments should fund anticipated operating needs for at least 12 months, based on its operating plans and milestone and royalty assumptions. It expected 2012 R&D expense to increase and G&A to remain at a similar level to 2011. GSK intended to begin regulatory filings for RELOVAIR in COPD and Europe asthma from mid-2012; the U.S. asthma regulatory path remained under discussion. These were expectations, not guaranteed outcomes.
- VIBATIV supply and commercialization: Manufacturing issues at the single-source supplier caused critical U.S. shortages; the supplier had GMP problems, and the European medicines committee recommended suspending the marketing authorization. Qualifying a replacement manufacturer could take 12–24 months. Theravance had no established sales force and was evaluating a new partner or other commercial approach.
- Pipeline and regulatory risk: RELOVAIR and LAMA/LABA remained in Phase 3, while the MABA program depended on further safety and enabling work. Not all RELOVAIR Phase 3 studies met their primary endpoint; GSK was investigating reports of fatal pneumonia, primarily at the highest dose. FDA policy and safety requirements for LABAs added uncertainty.
- Funding and obligations: The company expected continued losses and could need additional capital after the 12-month liquidity horizon. It may purchase up to $11 million of VIBATIV inventory, subject to release. Potential GSK milestone payments tied to VI commercialization could total up to $220 million; none were recorded as liabilities at year-end.
- Other exposures: Dependence on collaborators, contract manufacturers and CROs; clinical failure, competition, patent protection, pricing and reimbursement, and GSK’s significant ownership and governance rights. Deferred revenue and collaboration milestone accounting depend on estimated performance periods and contractual judgments.
Most important facts for investors to verify
- Confirm the issuer: the supplied document names Theravance, Inc., not Innoviva, and covers FY 2011 rather than only Q4.
- Check the status and timing of the expected approximately $125 million Q1 2012 deferred-revenue recognition, including any termination obligations and its noncash nature.
- Verify VIBATIV inventory release, replacement manufacturing progress, European authorization status and the company’s commercialization arrangements.
- Track actual R&D spending, operating cash burn and available liquidity against management’s 12-month funding assessment.
- Monitor GSK program results, regulatory submissions and potential milestone-payment timing, along with dilution and debt maturity terms.